Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab

Amanda Shreders, Richard W Joseph, Chengwei Peng, Fei Ye, Shilin Zhao, Igor Puzanov, Jeffrey A. Sosman, Douglas B. Johnson

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Patients with metastatic melanoma whose disease progresses on ipilimumab can clearly derive benefit from subsequent anti- programmed death-1 (PD-1). However, patients experience heterogeneous outcomes with ipilimumab, including rapid or delayed progression, and it is unclear whether patterns of ipilimumab progression influence subsequent clinical responses to anti-PD-1. We retrospectively reviewed data from 116 patients with metastatic melanoma who progressed on ipilimumab and were subsequently treated with pembrolizumab. The study objectives were to determine whether progression-free survival (PFS) with ipilimumab was associated with PFS, objective response rate (ORR), and clinical benefit rate (CBR; ORR stable disease) with pembrolizumab. Patients with PFS ≥90 days after treatment with ipilimumab generally had superior outcomes with subsequent pembrolizumab treatment compared with patients with PFS <90 days (ORR, 49% vs. 35%, P = 0.12; CBR, 66% vs. 46%, P = 0.03). Patients with prolonged ipilimumab benefit (PFS ≥ 180 days) had excellent outcomes with pembrolizumab compared with rapid progressors (PFS < 45 days; ORR, 55% vs. 25%; CBR, 80% vs. 25%; median PFS, 249 vs. 50 days). Using logistic regression models, PFS with ipilimumab was independently correlated with response to pembrolizumab (odds ratio, 1.22; 95% CI, 1.02-1.51). This study shows that prolonged PFS with ipilimumab predicts excellent outcomes with subsequent pembrolizumab treatment, offering valuable prognostic information for clinicians.

Original languageEnglish (US)
Pages (from-to)569-573
Number of pages5
JournalCancer immunology research
Volume4
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Disease-Free Survival
Melanoma
Logistic Models
pembrolizumab
ipilimumab
Therapeutics
Odds Ratio

ASJC Scopus subject areas

  • Cancer Research
  • Immunology

Cite this

Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab. / Shreders, Amanda; Joseph, Richard W; Peng, Chengwei; Ye, Fei; Zhao, Shilin; Puzanov, Igor; Sosman, Jeffrey A.; Johnson, Douglas B.

In: Cancer immunology research, Vol. 4, No. 7, 01.07.2016, p. 569-573.

Research output: Contribution to journalReview article

Shreders, Amanda ; Joseph, Richard W ; Peng, Chengwei ; Ye, Fei ; Zhao, Shilin ; Puzanov, Igor ; Sosman, Jeffrey A. ; Johnson, Douglas B. / Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab. In: Cancer immunology research. 2016 ; Vol. 4, No. 7. pp. 569-573.
@article{7d1c60e8a44244e5b2e5fea17473ba5d,
title = "Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab",
abstract = "Patients with metastatic melanoma whose disease progresses on ipilimumab can clearly derive benefit from subsequent anti- programmed death-1 (PD-1). However, patients experience heterogeneous outcomes with ipilimumab, including rapid or delayed progression, and it is unclear whether patterns of ipilimumab progression influence subsequent clinical responses to anti-PD-1. We retrospectively reviewed data from 116 patients with metastatic melanoma who progressed on ipilimumab and were subsequently treated with pembrolizumab. The study objectives were to determine whether progression-free survival (PFS) with ipilimumab was associated with PFS, objective response rate (ORR), and clinical benefit rate (CBR; ORR stable disease) with pembrolizumab. Patients with PFS ≥90 days after treatment with ipilimumab generally had superior outcomes with subsequent pembrolizumab treatment compared with patients with PFS <90 days (ORR, 49{\%} vs. 35{\%}, P = 0.12; CBR, 66{\%} vs. 46{\%}, P = 0.03). Patients with prolonged ipilimumab benefit (PFS ≥ 180 days) had excellent outcomes with pembrolizumab compared with rapid progressors (PFS < 45 days; ORR, 55{\%} vs. 25{\%}; CBR, 80{\%} vs. 25{\%}; median PFS, 249 vs. 50 days). Using logistic regression models, PFS with ipilimumab was independently correlated with response to pembrolizumab (odds ratio, 1.22; 95{\%} CI, 1.02-1.51). This study shows that prolonged PFS with ipilimumab predicts excellent outcomes with subsequent pembrolizumab treatment, offering valuable prognostic information for clinicians.",
author = "Amanda Shreders and Joseph, {Richard W} and Chengwei Peng and Fei Ye and Shilin Zhao and Igor Puzanov and Sosman, {Jeffrey A.} and Johnson, {Douglas B.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0281",
language = "English (US)",
volume = "4",
pages = "569--573",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab

AU - Shreders, Amanda

AU - Joseph, Richard W

AU - Peng, Chengwei

AU - Ye, Fei

AU - Zhao, Shilin

AU - Puzanov, Igor

AU - Sosman, Jeffrey A.

AU - Johnson, Douglas B.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Patients with metastatic melanoma whose disease progresses on ipilimumab can clearly derive benefit from subsequent anti- programmed death-1 (PD-1). However, patients experience heterogeneous outcomes with ipilimumab, including rapid or delayed progression, and it is unclear whether patterns of ipilimumab progression influence subsequent clinical responses to anti-PD-1. We retrospectively reviewed data from 116 patients with metastatic melanoma who progressed on ipilimumab and were subsequently treated with pembrolizumab. The study objectives were to determine whether progression-free survival (PFS) with ipilimumab was associated with PFS, objective response rate (ORR), and clinical benefit rate (CBR; ORR stable disease) with pembrolizumab. Patients with PFS ≥90 days after treatment with ipilimumab generally had superior outcomes with subsequent pembrolizumab treatment compared with patients with PFS <90 days (ORR, 49% vs. 35%, P = 0.12; CBR, 66% vs. 46%, P = 0.03). Patients with prolonged ipilimumab benefit (PFS ≥ 180 days) had excellent outcomes with pembrolizumab compared with rapid progressors (PFS < 45 days; ORR, 55% vs. 25%; CBR, 80% vs. 25%; median PFS, 249 vs. 50 days). Using logistic regression models, PFS with ipilimumab was independently correlated with response to pembrolizumab (odds ratio, 1.22; 95% CI, 1.02-1.51). This study shows that prolonged PFS with ipilimumab predicts excellent outcomes with subsequent pembrolizumab treatment, offering valuable prognostic information for clinicians.

AB - Patients with metastatic melanoma whose disease progresses on ipilimumab can clearly derive benefit from subsequent anti- programmed death-1 (PD-1). However, patients experience heterogeneous outcomes with ipilimumab, including rapid or delayed progression, and it is unclear whether patterns of ipilimumab progression influence subsequent clinical responses to anti-PD-1. We retrospectively reviewed data from 116 patients with metastatic melanoma who progressed on ipilimumab and were subsequently treated with pembrolizumab. The study objectives were to determine whether progression-free survival (PFS) with ipilimumab was associated with PFS, objective response rate (ORR), and clinical benefit rate (CBR; ORR stable disease) with pembrolizumab. Patients with PFS ≥90 days after treatment with ipilimumab generally had superior outcomes with subsequent pembrolizumab treatment compared with patients with PFS <90 days (ORR, 49% vs. 35%, P = 0.12; CBR, 66% vs. 46%, P = 0.03). Patients with prolonged ipilimumab benefit (PFS ≥ 180 days) had excellent outcomes with pembrolizumab compared with rapid progressors (PFS < 45 days; ORR, 55% vs. 25%; CBR, 80% vs. 25%; median PFS, 249 vs. 50 days). Using logistic regression models, PFS with ipilimumab was independently correlated with response to pembrolizumab (odds ratio, 1.22; 95% CI, 1.02-1.51). This study shows that prolonged PFS with ipilimumab predicts excellent outcomes with subsequent pembrolizumab treatment, offering valuable prognostic information for clinicians.

UR - http://www.scopus.com/inward/record.url?scp=84979738916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979738916&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0281

DO - 10.1158/2326-6066.CIR-15-0281

M3 - Review article

C2 - 27197063

AN - SCOPUS:84979738916

VL - 4

SP - 569

EP - 573

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 7

ER -